Cargando…

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients

B-cells play a key role in cancer suppression, particularly when aggregated in tertiary lymphoid structures (TLS). Here, we investigate the role of B-cells and TLS in endometrial cancer (EC). Single cell RNA-sequencing of B-cells shows presence of naïve B-cells, cycling/germinal center B-cells and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horeweg, Nanda, Workel, Hagma H., Loiero, Dominik, Church, David N., Vermij, Lisa, Léon-Castillo, Alicia, Krog, Ricki T., de Boer, Stephanie M., Nout, Remi A., Powell, Melanie E., Mileshkin, Linda R., MacKay, Helen, Leary, Alexandra, Singh, Naveena, Jürgenliemk-Schulz, Ina M., Smit, Vincent T. H. B. M., Creutzberg, Carien L., Koelzer, Viktor H., Nijman, Hans W., Bosse, Tjalling, de Bruyn, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927106/ https://www.ncbi.nlm.nih.gov/pubmed/35296668 http://dx.doi.org/10.1038/s41467-022-29040-x

Ejemplares similares

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
por: Vermij, Lisa, et al.
Publicado: (2020)

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
por: Vermij, Lisa, et al.
Publicado: (2023)

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)

The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning
por: Fremond, Sarah, et al.
Publicado: (2022)

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2021)

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
por: Wortman, Bastiaan G., et al.
Publicado: (2019)

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
por: Vermij, Lisa, et al.
Publicado: (2022)

Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer
por: Vermij, Lisa, et al.
Publicado: (2021)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

Incorporation of molecular characteristics into endometrial cancer management
por: Vermij, Lisa, et al.
Publicado: (2019)

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
por: Eggink, Florine A., et al.
Publicado: (2016)

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023)

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
por: Stelloo, Ellen, et al.
Publicado: (2016)

Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
por: Jamieson, Amy, et al.
Publicado: (2023)

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
por: Church, David N., et al.
Publicado: (2014)

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer
por: Workel, Hagma H., et al.
Publicado: (2020)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer
por: van Esterik, Manouk, et al.
Publicado: (2017)

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
por: Colombo, Nicoletta, et al.
Publicado: (2016)

Combined STING levels and CD103+ T cell infiltration have significant prognostic implications for patients with cervical cancer
por: Kol, Arjan, et al.
Publicado: (2021)

Prognostic image-based quantification of CD8CD103 T cell subsets in high-grade serous ovarian cancer patients
por: Paijens, S. T., et al.
Publicado: (2021)

QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
por: Van den Heerik, Anne Sophie V.M., et al.
Publicado: (2023)

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
por: Versluis, M A, et al.
Publicado: (2015)

Expression of CD39 Identifies Activated Intratumoral CD8+ T Cells in Mismatch Repair Deficient Endometrial Cancer
por: Lubbers, Joyce M., et al.
Publicado: (2022)

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2020)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2018)

Adjuvant Systemic Therapy after Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer: A Systematic Review and Meta-Analysis
por: Horeweg, Nanda, et al.
Publicado: (2021)

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2019)

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018)

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer
por: Peters, Elke E M, et al.
Publicado: (2019)

PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System
por: Corbeau, Anouk, et al.
Publicado: (2021)

Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome
por: Brunekreeft, Kim L., et al.
Publicado: (2020)

POLE proofreading mutation, immune response and prognosis in endometrial cancer
por: van Gool, Inge C., et al.
Publicado: (2015)

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
por: Kitson, Sarah, et al.
Publicado: (2017)

MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma
por: Tang, Michael C. Y., et al.
Publicado: (2023)

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
por: de Boer, S M, et al.
Publicado: (2018)

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy
por: Komdeur, Fenne L., et al.
Publicado: (2016)

Cancer of the corpus uteri: 2021 update
por: Koskas, Martin, et al.
Publicado: (2021)

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016)

Interpretation of somatic POLE mutations in endometrial carcinoma
por: León‐Castillo, Alicia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ue7kj8l02edco78o5kcg4q0h8p